## CLAIMS

- 1. A water-swellable linear polymer obtainable by reacting together
  - (a) a polyethylene oxide;
  - (b) a difunctional compound, and
  - (c) a difunctional isocyanate.
- 2. A polymer according to claim 1 wherein the polyethylene oxide has a number average molecular weight of 4000 to 35,000.
- 3. A polymer according to claim 1 wherein the polyethylene oxide has a number average molecular weight of 8000 to 12,000.
- 4. A polymer according to any preceding claim wherein the difunctional compound is a diamine or diol.
- 5. A polymer according to claim 4 wherein the diol is a  $C_5$  to  $C_{2\,0}$  diol.
- 6. A polymer according to claim 5 wherein the diol is a 1,10-decanediol.
- 7. A polymer according to claim 5 wherein the diol is 1,6-hexanediol, 1,12-dodecanediol or 1,16-hexadecanediol.

WO 2004/029125 PCT/GB2003/004208

8. A polymer according to any preceding claim wherein the ratio of components (a) to (b) to (c) in terms of equivalent weights is in the range 0.1-1.5 to 1 to 1.1-2.5.

43

- 9. A polymer according to claim 8 wherein the ratio is 0.2-0.9 to 1 to 1.2 1.9
- 10. A polymer according to claim 9 wherein the ratio is 0.5 0.9 to 1 to 1.5 1.9
- 11. A polymer according to any preceding claim which is swellable in water up to 500%.
- 12. A polymer according to any preceding claim which is swellable in water up to 1700%.
- 13. A polymer according to any preceding claim which is soluble in dichloromethane.
- 14. A method of making a polymer according to claim 1 which comprises reacting together components (a), (b) and (c).
- 15. A controlled release composition which comprises a polymer of any of claims 1 to 13 together with an active agent.

- 16. A composition according to claim 15 wherein the molecular weight of the active agent is in the range 200 to 20,000.
- 17. A composition according to claim 15 or 16 wherein the active agent is a prostaglandin.
- 18. A composition according to claim 15 or 16 wherein the active agent is terbutaline sulphate, clindamycin sulphate, oxytocin, misoprostol or progesterone.
- 19. A composition wherein the active agent is an H2 antagonist, antimuscaririe, receptor prostaglandin analogue, proton pump inhibitor, aminosalycilate, corticosteroid, chelating agent, cardiac glycoside, phosphodiesterase inhibitor, thiazide, diuretic, carbonic anhydrase inhibitor, antihypertensive, anti-cancer, antidepressant, calcium channel blocker, analgesic, opioid antiplatel, anticoagulant, fibrinolytic, antagonist, statin, adrenoceptor agonist, beta blocker, antihistamine, respiratory stimulant, micolytic, expectorant, benzodiazepine, barbiturate, anxiolytic, antipsychotic, tricyclic antidepressant, 5HT1 antagonist, 5HT, opiate, agonist, antiemetic, antiepileptic, dopaminergic, antibiotic, antifungal, anthelmintic, antiviral, antiprotozoal, antidiabetic, insulin, thyrotoxin, female sex hormone, male sex hormone, antioestrogen, hypothalamic, pituitary hormone, posterior pituitary hormone antagonist, antidiuretic hormone

WO 2004/029125 PCT/GB2003/004208

hormone antagonist, bisphosphonate, dopamine receptor stimulant, androgen, non-steroidal anti-inflammatory, immuno suppressant local anaesthetic, sedative, antipsioriatic, silver salt, topical antibacterial, vaccine.

20. A composition according to any of claims 15 to 18 in the form of a suppository, pessary, buccal insert or film.